Feature|Videos|October 8, 2025

Ensuring Quality & Compliance in Pharmaceutical Raw Materials: gChem’s Approach to ICH Q7 and Supply Chain Integrity

In this interview, Sandra Reid of gChem explains how PROCIPIENT®, its USP-grade DMSO, is uniquely manufactured under cGMP and ICH Q7 guidelines to ensure compliance, consistency, and quality across global pharmaceutical markets.

Sponsored by gChem

In this interview, Sandra Reid of gChem explains how the USP grade DMSO product, PROCIPIENT®, stands apart as the only dimethyl sulfoxide manufactured under cGMP conditions in full compliance with ICH Q7 API guidelines. The discussion explores why adherence to ICH Q7 is vital not just for active pharmaceutical ingredients but also for excipients and solvents, and how these practices ultimately safeguard the quality of finished drug products. Viewers will also learn about gChem’s distinctive processes, documentation standards, and supply chain controls that ensure consistency, compliance, and trust across global pharmaceutical markets.

Learning Objectives:

  • Explain the importance of ICH Q7 guidelines for API raw materials and their direct impact on final drug product quality.
  • Identify key cGMP processes that differentiate gChem’s PROCIPIENT® from other DMSO products not produced under ICH Q7 compliance.
  • Understand how gChem applies ICH Q7 principles to excipient and solvent applications, even when not explicitly required.
  • Describe the documentation, traceability, and controls gChem maintains when PROCIPIENT® is distributed through third-party agents or distributors.

Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.